Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 6295 entries
Sorted by: Best Match Show Resources per page
MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation.

OncoTargets and therapy

Jin P, Wong CC, Mei S, He X, Qian Y, Sun L.
PMID: 27499633
Onco Targets Ther. 2016 Jul 19;9:4387-96. doi: 10.2147/OTT.S106303. eCollection 2016.

The anticancer effect of MK-2206, an Akt inhibitor, has been explored in some types of cancers, but its effect on gastric cancer is unclear. In this study, we aimed to investigate its anticancer effect in gastric cancer cells. Cell...

Cite
Jin P, Wong CC, Mei S, et al. MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation. Onco Targets Ther. 2016;9:4387-96doi: 10.2147/OTT.S106303.
Jin, P., Wong, C. C., Mei, S., He, X., Qian, Y., & Sun, L. (2016). MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation. OncoTargets and therapy, 94387-96. https://doi.org/10.2147/OTT.S106303
Jin, Piaopiao, et al. "MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation." OncoTargets and therapy vol. 9 (2016): 4387-96. doi: https://doi.org/10.2147/OTT.S106303
Jin P, Wong CC, Mei S, He X, Qian Y, Sun L. MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation. Onco Targets Ther. 2016 Jul 19;9:4387-96. doi: 10.2147/OTT.S106303. eCollection 2016. PMID: 27499633; PMCID: PMC4959411.
Copy Download .nbib Format: NLM
Interface crosslinked poly(ethylene glycol)-poly(amino acid)s copolymer micelles for reduction-triggered release of doxorubicin.

Journal of controlled release : official journal of the Controlled Release Society

Wang S, Shen YL, Du BX, Li YL.
PMID: 27005103
J Control Release. 2015 Sep 10;213:e142. doi: 10.1016/j.jconrel.2015.05.240. Epub 2015 Aug 19.

No abstract available.

Cite
Wang S, Shen YL, Du BX, et al. Interface crosslinked poly(ethylene glycol)-poly(amino acid)s copolymer micelles for reduction-triggered release of doxorubicin. J Control Release. 2015;213:e142doi: 10.1016/j.jconrel.2015.05.240.
Wang, S., Shen, Y. L., Du, B. X., & Li, Y. L. (2015). Interface crosslinked poly(ethylene glycol)-poly(amino acid)s copolymer micelles for reduction-triggered release of doxorubicin. Journal of controlled release : official journal of the Controlled Release Society, 213e142. https://doi.org/10.1016/j.jconrel.2015.05.240
Wang, Sai, et al. "Interface crosslinked poly(ethylene glycol)-poly(amino acid)s copolymer micelles for reduction-triggered release of doxorubicin." Journal of controlled release : official journal of the Controlled Release Society vol. 213 (2015): e142. doi: https://doi.org/10.1016/j.jconrel.2015.05.240
Wang S, Shen YL, Du BX, Li YL. Interface crosslinked poly(ethylene glycol)-poly(amino acid)s copolymer micelles for reduction-triggered release of doxorubicin. J Control Release. 2015 Sep 10;213:e142. doi: 10.1016/j.jconrel.2015.05.240. Epub 2015 Aug 19. PMID: 27005103.
Copy Download .nbib Format: NLM
Erratum: Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [(14)C]-doxorubicin [Corrigendum].

Nanotechnology, science and applications

[No authors listed]
PMID: 27536080
Nanotechnol Sci Appl. 2016 Aug 05;9:47. doi: 10.2147/NSA.S112716. eCollection 2016.

[This corrects the article on p. 67 in vol. 8, PMID: 26715842.].

Cite
Erratum: Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [(14)C]-doxorubicin [Corrigendum]. Nanotechnol Sci Appl. 2016;9:47doi: 10.2147/NSA.S112716.
(2016). Erratum: Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [(14)C]-doxorubicin [Corrigendum]. Nanotechnology, science and applications, 947. https://doi.org/10.2147/NSA.S112716
"Erratum: Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [(14)C]-doxorubicin [Corrigendum]." Nanotechnology, science and applications vol. 9 (2016): 47. doi: https://doi.org/10.2147/NSA.S112716
Erratum: Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [(14)C]-doxorubicin [Corrigendum]. Nanotechnol Sci Appl. 2016 Aug 05;9:47. doi: 10.2147/NSA.S112716. eCollection 2016. PMID: 27536080; PMCID: PMC4976898.
Copy Download .nbib Format: NLM
Doxorubicin hydrochloride and curcumin loaded silk fibroin/hydroxypropylcellulose hydrogels for localized chemotherapy of cancer.

Journal of controlled release : official journal of the Controlled Release Society

Cao H, Yang Y, Shao Z.
PMID: 27005162
J Control Release. 2015 Sep 10;213:e39. doi: 10.1016/j.jconrel.2015.05.062. Epub 2015 Aug 19.

No abstract available.

Cite
Cao H, Yang Y, Shao Z. Doxorubicin hydrochloride and curcumin loaded silk fibroin/hydroxypropylcellulose hydrogels for localized chemotherapy of cancer. J Control Release. 2015;213:e39doi: 10.1016/j.jconrel.2015.05.062.
Cao, H., Yang, Y., & Shao, Z. (2015). Doxorubicin hydrochloride and curcumin loaded silk fibroin/hydroxypropylcellulose hydrogels for localized chemotherapy of cancer. Journal of controlled release : official journal of the Controlled Release Society, 213e39. https://doi.org/10.1016/j.jconrel.2015.05.062
Cao, Han, et al. "Doxorubicin hydrochloride and curcumin loaded silk fibroin/hydroxypropylcellulose hydrogels for localized chemotherapy of cancer." Journal of controlled release : official journal of the Controlled Release Society vol. 213 (2015): e39. doi: https://doi.org/10.1016/j.jconrel.2015.05.062
Cao H, Yang Y, Shao Z. Doxorubicin hydrochloride and curcumin loaded silk fibroin/hydroxypropylcellulose hydrogels for localized chemotherapy of cancer. J Control Release. 2015 Sep 10;213:e39. doi: 10.1016/j.jconrel.2015.05.062. Epub 2015 Aug 19. PMID: 27005162.
Copy Download .nbib Format: NLM
Doxorubicin-loaded polymeric micelles based on bioactive polypeptides: Suppress invasion of melanoma cells and alleviate doxorubicin-induced cardiotoxicity.

Journal of controlled release : official journal of the Controlled Release Society

Wang QM, Gao Z, Liu S, Fan B, Kang L, Huang W, Jin M.
PMID: 27005254
J Control Release. 2015 Sep 10;213:e91. doi: 10.1016/j.jconrel.2015.05.151. Epub 2015 Aug 19.

No abstract available.

Cite
Wang QM, Gao Z, Liu S, et al. Doxorubicin-loaded polymeric micelles based on bioactive polypeptides: Suppress invasion of melanoma cells and alleviate doxorubicin-induced cardiotoxicity. J Control Release. 2015;213:e91doi: 10.1016/j.jconrel.2015.05.151.
Wang, Q. M., Gao, Z., Liu, S., Fan, B., Kang, L., Huang, W., & Jin, M. (2015). Doxorubicin-loaded polymeric micelles based on bioactive polypeptides: Suppress invasion of melanoma cells and alleviate doxorubicin-induced cardiotoxicity. Journal of controlled release : official journal of the Controlled Release Society, 213e91. https://doi.org/10.1016/j.jconrel.2015.05.151
Wang, Qi-Ming, et al. "Doxorubicin-loaded polymeric micelles based on bioactive polypeptides: Suppress invasion of melanoma cells and alleviate doxorubicin-induced cardiotoxicity." Journal of controlled release : official journal of the Controlled Release Society vol. 213 (2015): e91. doi: https://doi.org/10.1016/j.jconrel.2015.05.151
Wang QM, Gao Z, Liu S, Fan B, Kang L, Huang W, Jin M. Doxorubicin-loaded polymeric micelles based on bioactive polypeptides: Suppress invasion of melanoma cells and alleviate doxorubicin-induced cardiotoxicity. J Control Release. 2015 Sep 10;213:e91. doi: 10.1016/j.jconrel.2015.05.151. Epub 2015 Aug 19. PMID: 27005254.
Copy Download .nbib Format: NLM
Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.

Transplantation direct

Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, Ten Berge IJ.
PMID: 27500242
Transplant Direct. 2015 Dec 15;2(1):e48. doi: 10.1097/TXD.0000000000000557. eCollection 2016 Jan.

Posttransplant lymphoproliferative disease (PTLD) is a potentially fatal complication after (solid organ) transplantation, which is highly associated with Epstein-Barr virus (EBV). The EBV-specific cytotoxic T cell response that is essential in controlling the virus in healthy individuals is suppressed...

Cite
Nijland ML, Kersten MJ, Pals ST, et al. Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct. 2015;2(1):e48doi: 10.1097/TXD.0000000000000557.
Nijland, M. L., Kersten, M. J., Pals, S. T., Bemelman, F. J., & Ten Berge, I. J. (2016). Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplantation direct, 2(1), e48. https://doi.org/10.1097/TXD.0000000000000557
Nijland, Marieke L, et al. "Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management." Transplantation direct vol. 2,1 (2016): e48. doi: https://doi.org/10.1097/TXD.0000000000000557
Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, Ten Berge IJ. Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct. 2015 Dec 15;2(1):e48. doi: 10.1097/TXD.0000000000000557. eCollection 2016 Jan. PMID: 27500242; PMCID: PMC4946499.
Copy Download .nbib Format: NLM
Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis.

OncoTargets and therapy

Lien CY, Chuang TY, Hsu CH, Lin CL, Wang SE, Sheu SJ, Chien CT, Wu CH.
PMID: 26060405
Onco Targets Ther. 2015 May 26;8:1193-210. doi: 10.2147/OTT.S82936. eCollection 2015.

OBJECTIVE: This study aimed to investigate whether the herbal formula B307 could alleviate doxorubicin (DOX)-induced acute cardiotoxicity. If so, we further unraveled possible molecular mechanisms of cardiac protection under treatment with the herbal formula B307.METHODS: Before the animal experiment,...

Cite
Lien CY, Chuang TY, Hsu CH, et al. Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. Onco Targets Ther. 2015;8:1193-210doi: 10.2147/OTT.S82936.
Lien, C. Y., Chuang, T. Y., Hsu, C. H., Lin, C. L., Wang, S. E., Sheu, S. J., Chien, C. T., & Wu, C. H. (2015). Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. OncoTargets and therapy, 81193-210. https://doi.org/10.2147/OTT.S82936
Lien, Chia-Ying, et al. "Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis." OncoTargets and therapy vol. 8 (2015): 1193-210. doi: https://doi.org/10.2147/OTT.S82936
Lien CY, Chuang TY, Hsu CH, Lin CL, Wang SE, Sheu SJ, Chien CT, Wu CH. Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. Onco Targets Ther. 2015 May 26;8:1193-210. doi: 10.2147/OTT.S82936. eCollection 2015. PMID: 26060405; PMCID: PMC4454207.
Copy Download .nbib Format: NLM
Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells.

Oncology letters

Huang L, Hu C, DI Benedetto M, Varin R, Liu J, Jin J, Wang L, Vannier JP, Janin A, Lu H, Li H.
PMID: 25663899
Oncol Lett. 2015 Mar;9(3):1287-1292. doi: 10.3892/ol.2014.2819. Epub 2014 Dec 22.

Multiple drug resistance remains an unsolved problem in cancer therapy. A previous study has demonstrated that the chemotherapeutic drug doxorubicin (Dox) induced upregulation of P-glycoprotein in endothelial cells, resulting in a 20-fold increase in drug resistance and reduced efficiency...

Cite
Huang L, Hu C, DI Benedetto M, et al. Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells. Oncol Lett. 2014;9(3):1287-1292doi: 10.3892/ol.2014.2819.
Huang, L., Hu, C., DI Benedetto, M., Varin, R., Liu, J., Jin, J., Wang, L., Vannier, J. P., Janin, A., Lu, H., & Li, H. (2015). Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells. Oncology letters, 9(3), 1287-1292. https://doi.org/10.3892/ol.2014.2819
Huang, Limin, et al. "Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells." Oncology letters vol. 9,3 (2015): 1287-1292. doi: https://doi.org/10.3892/ol.2014.2819
Huang L, Hu C, DI Benedetto M, Varin R, Liu J, Jin J, Wang L, Vannier JP, Janin A, Lu H, Li H. Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells. Oncol Lett. 2015 Mar;9(3):1287-1292. doi: 10.3892/ol.2014.2819. Epub 2014 Dec 22. PMID: 25663899; PMCID: PMC4315062.
Copy Download .nbib Format: NLM
Dual-frequency ultrasound activation of nanomicellar doxorubicin in targeted tumor chemotherapy.

Journal of medical ultrasonics (2001)

Hasanzadeh H, Mokhtari-Dizaji M, Zahra Bathaie S, Hassan ZM, Shahbazfar AA.
PMID: 27277765
J Med Ultrason (2001). 2014 Apr;41(2):139-50. doi: 10.1007/s10396-013-0484-x. Epub 2013 Oct 05.

INTRODUCTION: This study investigated the therapeutic effect of dual-frequency sonication (3 MHz and 28 kHz) at low intensity levels in combination with micellar doxorubicin in the treatment of a tumor model of spontaneous breast adenocarcinoma in Balb/c mice.METHODS: We...

Cite
Hasanzadeh H, Mokhtari-Dizaji M, Zahra Bathaie S, et al. Dual-frequency ultrasound activation of nanomicellar doxorubicin in targeted tumor chemotherapy. J Med Ultrason (2001). 2013;41(2):139-50doi: 10.1007/s10396-013-0484-x.
Hasanzadeh, H., Mokhtari-Dizaji, M., Zahra Bathaie, S., Hassan, Z. M., & Shahbazfar, A. A. (2014). Dual-frequency ultrasound activation of nanomicellar doxorubicin in targeted tumor chemotherapy. Journal of medical ultrasonics (2001), 41(2), 139-50. https://doi.org/10.1007/s10396-013-0484-x
Hasanzadeh, Hadi, et al. "Dual-frequency ultrasound activation of nanomicellar doxorubicin in targeted tumor chemotherapy." Journal of medical ultrasonics (2001) vol. 41,2 (2014): 139-50. doi: https://doi.org/10.1007/s10396-013-0484-x
Hasanzadeh H, Mokhtari-Dizaji M, Zahra Bathaie S, Hassan ZM, Shahbazfar AA. Dual-frequency ultrasound activation of nanomicellar doxorubicin in targeted tumor chemotherapy. J Med Ultrason (2001). 2014 Apr;41(2):139-50. doi: 10.1007/s10396-013-0484-x. Epub 2013 Oct 05. PMID: 27277765.
Copy Download .nbib Format: NLM
Rituximab-Induced Acute ST Elevation Myocardial Infarction.

The Ochsner journal

Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E.
PMID: 26130984
Ochsner J. 2015;15(2):187-90.

BACKGROUND: Rituximab has rarely been associated with acute coronary syndrome (ACS). We report the case of a patient in whom rituximab, a monoclonal antibody used to treat lymphomas of B-cell origin, induced ST elevation myocardial infarction.CASE REPORT: A 46-year-old...

Cite
Keswani AN, Williams C, Fuloria J, et al. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15(2):187-90
Keswani, A. N., Williams, C., Fuloria, J., Polin, N. M., & Jahangir, E. (2015). Rituximab-Induced Acute ST Elevation Myocardial Infarction. The Ochsner journal, 15(2), 187-90.
Keswani, Amit N, et al. "Rituximab-Induced Acute ST Elevation Myocardial Infarction." The Ochsner journal vol. 15,2 (2015): 187-90.
Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15(2):187-90. PMID: 26130984; PMCID: PMC4482563.
Copy Download .nbib Format: NLM
Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines.

Frontiers in bioengineering and biotechnology

Parmar MB, Aliabadi HM, Mahdipoor P, Kucharski C, Maranchuk R, Hugh JC, Uludağ H.
PMID: 25763370
Front Bioeng Biotechnol. 2015 Feb 16;3:14. doi: 10.3389/fbioe.2015.00014. eCollection 2015.

The cell cycle proteins are key regulators of cell cycle progression whose deregulation is one of the causes of breast cancer. RNA interference (RNAi) is an endogenous mechanism to regulate gene expression and it could serve as the basis...

Cite
Parmar MB, Aliabadi HM, Mahdipoor P, et al. Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines. Front Bioeng Biotechnol. 2015;3:14doi: 10.3389/fbioe.2015.00014.
Parmar, M. B., Aliabadi, H. M., Mahdipoor, P., Kucharski, C., Maranchuk, R., Hugh, J. C., & Uludağ, H. (2015). Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines. Frontiers in bioengineering and biotechnology, 314. https://doi.org/10.3389/fbioe.2015.00014
Parmar, Manoj B, et al. "Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines." Frontiers in bioengineering and biotechnology vol. 3 (2015): 14. doi: https://doi.org/10.3389/fbioe.2015.00014
Parmar MB, Aliabadi HM, Mahdipoor P, Kucharski C, Maranchuk R, Hugh JC, Uludağ H. Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines. Front Bioeng Biotechnol. 2015 Feb 16;3:14. doi: 10.3389/fbioe.2015.00014. eCollection 2015. PMID: 25763370; PMCID: PMC4329877.
Copy Download .nbib Format: NLM
Erratum: Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum].

OncoTargets and therapy

[No authors listed]
PMID: 25792842
Onco Targets Ther. 2015 Mar 09;8:593. doi: 10.2147/OTT.S80592. eCollection 2015.

[This corrects the article on p. 1409 in vol. 7, PMID: 25143745.].

Cite
Erratum: Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]. Onco Targets Ther. 2015;8:593doi: 10.2147/OTT.S80592.
(2015). Erratum: Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]. OncoTargets and therapy, 8593. https://doi.org/10.2147/OTT.S80592
"Erratum: Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]." OncoTargets and therapy vol. 8 (2015): 593. doi: https://doi.org/10.2147/OTT.S80592
Erratum: Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]. Onco Targets Ther. 2015 Mar 09;8:593. doi: 10.2147/OTT.S80592. eCollection 2015. PMID: 25792842; PMCID: PMC4360789.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 6295 entries